Geode Capital Management, LLC Iovance Biotherapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 5,506,617 shares of IOVA stock, worth $44.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,506,617

Previous 5,037,098 9.32%

Holding current value

$44.2 Million

Previous $41 Million 99.28%

% of portfolio

0.01%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$7.59 - $17.47 $3.56 Million - $8.2 Million	469,519 Added 9.32%	5,506,617 $81.6 Million
Q4 2023 Feb 13, 2024	BUY	$3.3 - $8.89 $949,367 - $2.56 Million	287,687 Added 6.06%	5,037,098 $41 Million
Q3 2023 Nov 13, 2023	BUY	$4.44 - $8.79 $2.71 Million - $5.37 Million	611,049 Added 14.77%	4,749,411 $21.6 Million
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $5.89 Million - $9.96 Million	1,098,929 Added 36.16%	4,138,362 $29.1 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $1.29 Million - $1.92 Million	233,052 Added 8.3%	3,039,433 $18.6 Million

Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $754,333 - $1.34 Million	134,223 Added 5.02%	2,806,381 $17.9 Million
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $307,523 - $423,046	32,269 Added 1.22%	2,672,158 $25.6 Million
Q2 2022 Aug 12, 2022	BUY	$6.38 - $18.33 $4.73 Million - $13.6 Million	741,702 Added 39.07%	2,639,889 $29.1 Million
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $623,654 - $962,181	50,376 Added 2.73%	1,898,187 $31.6 Million
Q4 2021 Feb 11, 2022	BUY	$16.55 - $27.63 $1.02 Million - $1.71 Million	61,799 Added 3.46%	1,847,811 $35.3 Million
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $879,608 - $1.15 Million	-43,224 Reduced 2.36%	1,786,012 $44 Million
Q2 2021 Aug 13, 2021	BUY	$16.33 - $33.07 $1.74 Million - $3.52 Million	106,413 Added 6.18%	1,829,236 $47.6 Million
Q1 2021 May 12, 2021	BUY	$28.67 - $52.59 $1.81 Million - $3.31 Million	62,962 Added 3.79%	1,722,823 $54.5 Million
Q4 2020 Feb 12, 2021	BUY	$28.04 - $50.26 $2.66 Million - $4.77 Million	94,876 Added 6.06%	1,659,861 $77 Million
Q3 2020 Nov 13, 2020	SELL	$27.75 - $36.3 $1 Million - $1.31 Million	-36,161 Reduced 2.26%	1,564,985 $51.5 Million
Q2 2020 Aug 13, 2020	SELL	$27.21 - $41.0 $4.66 Million - $7.02 Million	-171,223 Reduced 9.66%	1,601,146 $44 Million
Q1 2020 May 14, 2020	BUY	$19.54 - $38.85 $2.25 Million - $4.48 Million	115,311 Added 6.96%	1,772,369 $53.1 Million
Q4 2019 Feb 13, 2020	BUY	$17.95 - $29.41 $1.39 Million - $2.28 Million	77,657 Added 4.92%	1,657,058 $45.9 Million
Q3 2019 Nov 12, 2019	SELL	$17.99 - $26.0 $956,258 - $1.38 Million	-53,155 Reduced 3.26%	1,579,401 $28.7 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $1.56 Million - $3.9 Million	159,148 Added 10.8%	1,632,556 $40 Million
Q1 2019 May 14, 2019	BUY	$8.41 - $11.26 $1.08 Million - $1.45 Million	128,706 Added 9.57%	1,473,408 $14 Million
Q4 2018 Feb 13, 2019	BUY	$7.51 - $11.93 $3.5 Million - $5.56 Million	466,218 Added 53.07%	1,344,702 $11.9 Million
Q3 2018 Nov 13, 2018	BUY	$11.25 - $17.7 $1.33 Million - $2.09 Million	118,176 Added 15.54%	878,484 $9.88 Million
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $1.29 Million - $1.76 Million	103,594 Added 15.77%	760,308 $9.73 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $669,635 - $1.61 Million	82,671 Added 14.4%	656,714 $11.1 Million
Q4 2017 Feb 13, 2018	BUY	$6.65 - $9.25 $326,854 - $454,646	49,151 Added 9.36%	574,043 $4.59 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $32,235 - $61,936	7,244 Added 1.4%	524,892 $4.07 Million
Q2 2017 Aug 14, 2017	BUY	N/A	517,648	517,648 $3.8 Million

Others Institutions Holding IOVA

# of Institutions

303

Shares Held

221M

Call Options Held

3.05M

Put Options Held

1.6M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.27B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Iovance Biotherapeutics, Inc. Transaction History